Doxorubicin Hydrochloride/Iboctadekin

N/A

Report date: 2022/09/19 14:16:47

Base Information

Drug NameDoxorubicin Hydrochloride/Iboctadekin
Drug Alias NameIboctadekin/Doxorubicindoxorubicin/iboctadekinIboctadekin/Doxorubicin Hydrochloride
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTopoisomerase II inhibitorsDNA intercalatorsInterleukin 18 receptor agonists
TargetsInterleukin 18 receptorTopoisomerase IIDNA
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes IboctadekinDoxorubicin Hydrochloride
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A